Treatment for Alopecia Areata Receives FDA Approval On June 13, 2022, the U.S. Food and Drug administration (FDA) approved Olumiant (baricitinib) for the treatment of severe alopecia areata in adults, marking the first-ever approved treatment for the disease. Baricitinib is a member of the class of drugs known as Janus kinase (JAK) inhibitors, which are approved for other conditions, such as rheumatoid arthritis, ulcerative colitis, and atopic dermatitis (eczema). The availability of this approved oral medication represents a new choice among treatment options for the alopecia areata community. Olumiant (baricitinib) is the first of several JAK inhibitors that have completed late-stage clinical trials for alopecia areata and that are expected to undergo FDA review. This means that more treatments are on the horizon for alopecia areata patients. Read the rest of this article and the full issue of the Enews here>>>
